Technical Advisory Board 技术顾问委员会
Professor Hamid Aghvami (音译：哈米德·阿格瓦米)
Professor Aghvami is Professor in Telecommunications Engineering and Director of the Centre for Telecommunications Research at King's College London. He has been a member of the academic staff at King's since 1984 and now leads a research team working on numerous mobile and personal communications projects. He carries out consulting work on digital radio communications systems, is a Fellow of the Royal Academy of Engineering, Fellow of the IEE, and Fellow of the IEEE, and has been Visiting Professor at NTT Radio Communication Systems Laboratories and Senior Research Fellow at BT Laboratories.
Aghvami教授是伦敦大学国王学院的通信工程系教授，同时也是该校通信研究中心的主任，自1984年起就一直是国王学院的学术成员，现在正领导一个研究团队从事多个移动和个人通信项目的研究。他从事无线电数字通信系统的咨询工作，是皇家工程学院、电气工程师学会（IEE）和电气电子工程师学会（IEEE）的资深会员，并且一直是NTT（日本电报电话公司）无线电通信系统实验室的客座教授和BT公司实验室的高级研究员。
Professor Gehan Amaratunga (音译：吉亨·阿马拉通加)
Professor Amaratunga is Professor of Engineering and Head of Electronics, Power and Energy at the University of Cambridge. Since receiving his PhD from Cambridge in 1983, he has held academic and research positions at Southampton University, the University of Liverpool and Stanford University in California. He is an elected fellow of the Royal Academy of Engineering and a recipient of awards from that body, the IEE and the Royal Society. He has a long record of successful collaborations with industry partners in Europe, the USA and Asia. He has also acted as an expert in patent litigation for multinationals and as an adviser to leading investment firms. He has published over 400 papers and is an inventor on 22 patents. Professor Amaratunga is also CTO and co-founder of the venture-capital backed start-up, Cambridge Semiconductor (CamSemi). CamSemi's expertise is in power management integrated circuits for optimised energy-efficient off-line power conversion. Its solutions are designed to help manufacturers of mains-powered electronics develop smaller, lighter and more energy-efficient products while also reducing their design timescales and system costs. It raised its series A funding in 2003 and has locations in Cambridge and Taiwan. CamSemi is one of the success stories of spin-offs from Cambridge University. The company has 50 employees worldwide and sold to date over 50M power IC units for power supplies. It has won a number of national and international awards recognising its technologies, cost-efficient products and commitment to the environment, including "University Spin-out of the Year" in the New Energy Awards 2009, Start-up of the Year from the National Microelectronics Institute in 2009, has been included four years running in Silicon 60, a list of the world's most promising technology start-ups researched and published annually by EE Times, and in 2008 was judged as Europe's third most important cleantech company by the Guardian. He has also co-founded, with his research students, Enecsys Ltd (www.enecsys.com). It has developed a new micro-inverter technology which allows an individual solar panel to be connected directly to the AC power grid. This enables a solar power plant to be built up in a modular basis while maximising the energy harvested over time. A special feature of the technology is its 25 year life time capability which allows the inverter to be built into the solar panel and deployed outside in the same weather conditions. Enecsys won the Cambridge Entrepreneurs Business Plan competition in 2003 and following grant and seed round funding to develop the technology, completed a series A VC round of $14M in 2009 to introduce the product to the market. His other spin out venture with his colleagues was Nanoinstruments, a company set up to commercialise carbon nanotube growth equipment emanating from his research. Nanoinstruments was acquired by Aixtron AG in 2007.
Amaratunga教授是剑桥大学工程系教授，并且担任电子、电力和能源系的负责人。他于1983年从剑桥大学获得博士学位后，曾先后在南安普敦大学、利物浦大学、加利福尼亚的斯坦福大学担任学术和研究职务。他是被推选出来的皇家工程学院的资深会员，并且获得了由皇家工程学院、电气工程师学会和皇家学会颁发的多种奖项。他与欧洲、美国和亚洲的业界伙伴进行过多次成功的协作，此外，还担任多家跨国公司的专利诉讼专家和多家顶级投资公司的顾问。迄今为止，他已发表了400多篇论文，并且拥有22项发明专利，还是一家剑桥的半导体公司——英商康桥半导体（一家由创投资本支持的新创公司）的首席技术官和共同创始人。英商康桥半导体公司的专长是开发用于优化的高能效离线能耗转换的功率管理集成电路。该公司的解决方案旨在帮助电源驱动型电子设备的制造商开发出更小、更轻且能效更高的产品，同时缩短设计时间，降低系统成本。公司于2003年完成了第一轮募资，在剑桥和台湾都设有办事处。英商康桥半导体是从剑桥大学分离出来的众多创业公司中的成功事例之一，目前在全世界拥有50名雇员，迄今为止已售出5000多万个电源集成电路单元，获得若干国家级和国际级奖项。这些奖项认可该公司的技术、有成本效益的产品以及对环境保护的承诺，包括2009年新能源奖中的“年度大学分离企业”、国家微电子学会在2009年颁发的年度创业企业大奖。此外，公司曾连续4年入选“Silicon 60”榜单（这是一份由《EE Times》每年研究并且公布的全世界最有前途的技术型创业公司名单），在2008年被英国《卫报》评为欧洲最重要的清洁技术公司第三名。Amaratunga还与他的研究学生一起创立了Enecsys Ltd公司（www.enecsys.com）。该公司开发出了一种新型的微换流器技术，可以将单独的太阳能电池板直接连接到交流电网上，这样就能用模块的方式建造太阳能发电厂，同时可以最大程度地收集能源。该技术的特点之一在于使用寿命长达25年，这些变流器可以被嵌入到太阳能电池板中，并被部署到相同的气候条件中。Enecsys赢得了2003剑桥企业家商业计划大赛、随后得到了开发该技术的基金和种子轮融资，于2009年完成了第一轮1400万美元创投资本融资，以将其产品推向市场。此外，Amaratunga还和他的同事们创立了另一个大学分离公司——Nanoinstruments，该公司旨在将他的研究成果碳纳米管生长设备商业化。Nanoinstruments公司于2007年被德国爱思强股份有限公司（Aixtron AG）收购。
英国皇家学会(FRS)和皇家医学会的资深会员(FmedSci) Professor Anthony Barrett (音译：安东尼·巴雷特教授)
Professor Barrett is the Sir Derek Barton Professor of Synthesis, Glaxo Professor of Organic Chemistry and Director of the Wolfson Centre for Organic Chemistry in Medical Science at Imperial College of Science, Technology and Medicine. He is a Fellow of the Royal Society and a Fellow of the Academy of Medical Sciences, and has served as a member of the Chemicals Panel of the Office of Science and Technology's Foresight Programme. He is founder-director of a spin-out from Imperial College (which was advised by Company Guides Limited), has experience of US biotech start-ups, and has experience of working as a consultant and scientific advisory board member for a number of US and European companies.
Barrett教授是帝国理工学院医学系化学合成专业的Derek Barton爵士教授、有机化学专业的Glax教授和Wolfson有机化学中心主任。此外，他还是皇家学会和医学会的资深会员，是英国科学与技术办公室前瞻计划化学组的成员。Barrett教授是一家由帝国理工学院分离出来的公司的创始人兼董事（该公司由企业指引有限公司（Company Guides Limited）提供咨询）。他在美国的生物技术新创公司有丰富的工作经验，并曾担任多家美国和欧洲公司的顾问和技术顾问委员会的成员。
英国皇家学会的资深会员Professor Sir Michael Brady (音译: 迈克尔·布雷迪)
Professor Sir Michael Brady FRS, FREng, FMedSci, FIET, FInstP, FBCS is BP Professor of Information Engineering at the University of Oxford, which he joined from MIT in 1985. His research has for the past 15 years concentrated on medical and molecular image analysis, previously robotics. He was awarded the IEE Faraday Medal for 2000 and the IEEE Third Millennium Medal for the UK. He was awarded the Henry Dale Prize (for "outstanding work on a biological topic by means of an original multidisciplinary approach") by the Royal Institution in 2005. Mike was knighted in the New Year's honours list for 2003 and has honorary doctorates from 5 universities and from Université Paul Sabatier, Toulouse. Mike has a strong commitment to entrepreneurial activity. He serves as a non-executive director and Deputy Chairman of Oxford Instruments plc, until December 2003 he was Senior Independent Director of AEA Technology plc, and he is a director of Isis Innovation (Oxford University's intellectual property company). Mike is a founding Director of the start-up companies Guidance, which develops navigation systems for mobile robots and for dynamic ship positioning as well as electronic tags for offenders, and Mirada Solutions Limited, which develops medical image analysis software, in particular Reveal MVS for multimodal image fusion. Mirada Solutions was acquired in 2003 by CTI Molecular Imaging Inc (NASDAQ) and CTI was acquired in turn by Siemens in April 2005, becoming Siemens Molecular Imaging. Most recently, Mike became Senior Independent Director of the start-up company Ixico, which provides image analysis services to the pharmaceutical industry, and is a Director of Dexela, which is developing a novel 3D mammography system for more reliable and early detection of breast cancer. Mike is Chairman of the Science Advisory Board of Technikos.
Michael Brady 爵士教授是英国皇家学会、皇家工程学会、医学会、英国工程及技术学会、英国物理学会和英国计算机学会的资深会员。Michael于1985年离开麻省理工学院加入牛津大学，现在是牛津大学信息工程系教授。过去15年，他的研究专注于医学和分子图像分析领域。此前，他主要从事机器人领域的研究。Brady 教授曾被授予电气工程师学会2000年度“法拉第”奖章和电气电子工程师学会的英国第三个千年奖章。此外，他于2005年被英国皇家研究院授予Henry Dale奖，以表彰他“通过原创性的多学科方法对一个生物学主题所做的卓越工作”。在2003年新年授勋名录中，Michael先生被授予爵士，还被5所大学和图卢兹第三大学授予名誉博士学位。Michael教授非常乐于从事创业活动，他担任牛津仪器公共股份集团（Oxford Instruments plc）的非执行董事和副董事长。2003年12月前，他还曾担任AEA技术公共公司（AEA Technology plc）的资深独立董事，还是Isis创新公司（牛津大学的知识产权公司）的董事。此外，Brady教授还是Guidance这家新创公司的创始董事。这家公司开发活动机器人和动态船只定位用的导航系统以及针对罪犯的电子标签。他还是Mirada解决方案有限公司（Mirada Solutions Limited）的创始董事，该公司主要开发医学图像分析软件，尤其是多模态图像融合软件Reveal MVS。Mirada解决方案有限公司于2003年被CTI分子成像公司（CTI Molecular Imaging Inc）（NASDAQ上市）收购。此后，CTI分子成像公司又于2005年4月被西门子收购，成为西门子分子成像公司。最近，Michael教授还成为新创公司Ixico的资深独立董事。该公司为制药行业提供图像分析服务。此外，他还是Dexela公司的董事，该公司正在开发一种新型三维乳房造影系统，以便能够更可靠、更早地检测出乳腺癌。同时，他还担任Technikos公司的技术顾问委员会主席一职。
Dr David Chiswell OBE (获得大英帝国勋章) (音译: 戴维.齐斯维尔博士)
Dr Chiswell is the founder and former CEO of Cambridge Antibody Technology (CAT), a life science start-up that was founded in 1990, grew to over 250 employees and listed on the London Stock Exchange and Nasdaq. In June 2006 CAT was acquired by AstraZeneca for US$1.32bn. David retired from CAT in 2002 and since then has been a director of a number of start-up and early stage companies, including chairman of Arrow Therapeutics Ltd (acquired by AstraZeneca for US$150m in March 2007); non-executive director of Arakis Ltd and subsequently chairman of Sosei Company Ltd (Arakis was acquired by Sosei for US$150m in July 2005); chairman of DanioLabs (acquired by Vastox plc in March 2007 for £15m); and executive chairman of Nabriva GmbH, the specialist antibody research company spun out from the Vienna-based Antibiotic Research Institute and Sandoz in January 2006. He has served on the Board of the USA Biotechnology Industry Association's 'Emerging Companies Section' Governing Body, was chairman of the UK's BioIndustry Association (BIA) and was a member of the steering group of the Bioscience Innovation and Growth Team (which was set up by the DTI, the Department of Health and the BIA).
Chiswell 博士是剑桥抗体技术公司（CAT）的创始人及前任首席执行官。剑桥抗体技术公司是于1990年创立的生命科学公司，现在拥有250多名雇员，并先后在伦敦证券交易所和纳斯达克证券上市。2006年6月，剑桥抗体技术公司被阿斯利康公司（AstraZeneca）以13.2亿美元收购。David于2002年从剑桥抗体技术公司退休，此后，曾先后在多家新创公司和处于早期发展阶段的公司担任董事，其中包括：箭理疗（Arrow Therapeutics）有限公司的董事长（该公司于2007年3月被阿斯利康以1.5亿美元收购）；阿拉其斯（Arakis）有限公司的非执行董事，之后成为索赛（Sosei）有限公司的主席（Arakis于2005年7月被Sosei以1.5亿美元收购）；DanioLabs公司的主席（该公司于2007年3月被Vastox公共股份公司以1.5亿美元收购）；Nabriva股份有限公司的执行主席，该公司是专注于抗体研究的公司，于2006年1月由位于维也纳的抗生素研究所和Sandoz公司分离出来成立。此外，博士还曾在美国生物技术行业协会的“新兴公司部门”主管团体的委员会任职，并且曾任英国生物工业协会（BIA）主席、生物科学创新和发展小组督导团的成员（该小组由英国贸易工业部、卫生部和英国生物工业协会共同成立）。
Peter Gibson (音译：彼得·吉布森)
Peter Gibson has substantial experience in the medical device sector, with particular focus on orthopaedics, and has a particular interest in medical technology start-ups. From 1980-1985 he was Managing Director of Zimmer UK Ltd and International Vice President of Zimmer Inc, a subsidiary of Bristol Myers. In 1985 he founded Corin Medical Ltd and became Chairman and CEO. Corin is a specialist in reconstructive orthopaedic devices, with products that include a wide range of orthopaedic implants, together with surgical instruments, minimally invasive systems and surgical navigation support. Peter led the flotation of Corin Group PLC on the London Stock Exchange in 2002 and retired from Corin in late 2003. Since Corin, Peter has been involved with a number of companies in the medical device sector, both as Chairman and Non-Executive Director. He is a Companion Fellow of the British Orthopaedic Association.
Peter Gibson在医疗设备领域，尤其是骨科医疗器械领域经验丰富，对医疗器械技术领域的新创公司非常感兴趣。1980至1985年间，他曾担任捷迈（Zimmer）英国有限公司的董事总经理和捷迈公司（百时美（Bristol Myers）旗下的一家子公司）的国际副总裁。1985年，他创立了科润（Corin）医疗有限公司并且担任该公司的董事长兼首席执行官。科润公司是重建矫形外科器械的专家，其产品包括范围众多的矫形外科植入物、手术器械、微创系统以及外科手术导航支持。Peter带领科润集团公共股份有限公司（Corin Group PLC）于2002年在伦敦证券交易所成功上市，于2003年晚些时候从科润公司退职。此后，他曾在多家医疗器械公司任职，担任主席和非执行董事。他是英国矫形外科协会的会员。
Derek Harbour (音译：德里克·哈伯)
Derek has experience of running companies in both small and large groups and experience of venture capital backed businesses. He is currently executive chairman of Sonatest NDE Group plc and has non-executive experience in small ‘high-tech’ companies. He was formerly a partner in the 3i plc Technology Team for 10 years where he provided commercial and technical expertise in both investing and developing growing technology companies in the UK and Europe. His specialisation is electronics, both hardware and software, where he was involved with a number of successful investments. He spent the first 10 years of his career in operations in large electronics based organisations (GEC, Emerson, etc) and then the next 15 years running technology based companies in the automation, robotics and control & instrumentation fields. He has also advised BERR (the UK Government Department for Business, Enterprise & Regulatory Reform) on the formation of their Knowledge Transfer Networks.
Derek在经营小型公司和大型集团公司方面均有丰富经验，在经营由创投资本支持的公司方面也有丰富的经验。他目前担任Sonatest NDE集团公共有限公司（Sonatest NDE Group plc）的执行总裁，并且曾经担任多家小型“高科技”公司的非执行总裁。此前，他曾经担任3i公司技术团队的合伙人一职长达10年之久，在此期间，他利用自己的商业和技术专长在英国和欧洲投资并且发展增长型技术的公司。他的专业领域是电子学，包括硬件和软件，曾在该领域参与过很多成功的投资。他职业生涯的最初10年是在多家大型的电子公司中（包括英国通用电气公司（GEC）、爱默生等公司）度过的。此后的15年，他在自动化、机器人和控制与仪器仪表等领域负责技术公司的运营，还曾向英国商业、企业和管理改革部（BERR）就如何建立知识转移网络提供过咨询建议。
Clive Hudson (音译：克莱夫·赫德森)
Clive has many years experience starting and running technology companies. He was responsible for the launch of US Robotics in the UK and Germany and then as European Vice President, responsible for the running of the $500m+ a year business. He was also responsible for the European launch of Palm Computing, when US Robotics acquired Palm, and eventually oversaw the transition of both companies to 3Com Corporation when US Robotics and Palm were acquired in 1997. Clive became European Vice President of 3Com’s Client Access Business Unit with responsibility for approximately €2bn of annual revenues and 400 staff. Since then, Clive has been involved with several enterprises, including the start up of the specialist networking company Entrega Technologies, which was sold to Intel, the launch of US ADSL Company Actiontec Inc, and the European re-launch of MP3 manufacturer Rio Audio.
Clive在创立和经营技术型公司方面有多年经验，曾负责在英国和德国建立美国机器人公司（US Robotics）的分部，随后又担任欧洲部的副总裁，负责经营年价值达到5亿多美元的业务。在美国机器人公司将Palm收购后，他还曾负责在欧洲建立Palm Computing公司的分公司，在美国机器人公司和Palm于1997年被3Com公司收购后，Clive又负责这两家公司向3Com公司的过渡。此后，他成为3Com公司的客户接触业务单位的欧洲副总裁，负责管理这家年收入达20亿欧元和拥有400名员工的公司。在此之后，Clive曾在多家企业任职，包括建立专业的联网公司Entrega Technologies（该公司后来被卖给了英特尔公司），推出美国的一家经营宽带的Actiontec公司，并且在欧洲重新推出MP3的制造商Rio Audio公司。
Nick Kingsbury (音译：尼克·金斯伯里)
Nick has extensive experience in the global software industry, both as a venture capitalist and successful technology entrepreneur. He joined 3i in 1999 to head up the Software Sector internationally for 3i, leaving in 2007. His role at 3i involved setting the strategy for investment in software and he was a key member of the team reviewing all software investments globally. He also worked closely with the major IT corporates to ensure that 3i understood their strategies, and made introductions at very senior levels for 3i's portfolio companies. Prior to joining 3i, Nick founded and ran a systems integration company and software house for over 10 years. He sold the business to a UK software company Staffware plc, and helped take the company to an IPO on the London Stock Exchange. He has chaired an international standard body, the Workflow Management Coalition, and remains a lifetime fellow of this organisation. More recently Nick has been advising early stage companies (including a spin out from Imperial College London) on fundraising, successfully completing 7 investment rounds in 2 years, and also serves on the board of a quoted international software company, Objective Corporation Limited.
Nick在全球软件业无论是作为创投资本家还是成功的技术企业家，都有丰富的经验。他于1999年加入3i公司，掌管3i的国际软件业，2007年离开。他在3i的职责包括制定软件投资战略，同时也是负责回顾全球所有软件投资这一团队的关键成员。他还与主要的IT公司密切合作，以确保3i能理解这些公司的战略，并且在很高层次上为3i投资组合中的公司做推介。在加入3i前，Nick创立了一家系统集成和软件公司并且经营了10年多；后来他把这家公司出售给了英国的一家软件公司Staffware，并且帮助Staffware在伦敦证交所顺利上市。他一直担任国际标准机构“工作流管理联盟”的主席并且是这家组织的终身高级会员。近年来Nick为成立初期的公司（其中包括伦敦帝国理工学院的一家派生公司）就资金募集提供建议，2年内已经成功完成了7轮投资。此外他还在一家上市国际软件公司Objective Corporation Limited担任董事。
Peter MacLean (音译：彼得·麦克林)
Peter MacLean has more than 40 years experience of the IT software and services industry. He is currently chairman and chief executive of an IT services business, 365 iT plc (formerly Impera plc) where he is executing a buy and build strategy. Previously, as chief executive, he led Guardian iT plc through a joint venture, a management buyout and then a listing onto the main market of the London Stock Exchange. During a period of 14 years he grew Guardian from a turnover of £0.5 million to £120 million with 700 employees operating in 12 countries in Europe, South Africa and Japan. Prior to Guardian he was a main board director of a publicly listed software services group, Sherwood International plc, for 10 years and managing director of their insurance, financial services and local government subsidiaries.
Peter MacLean在IT软件和服务业拥有40多年的工作经验，现在是365 iT公共有限公司这家IT公司（前身是Impera公共有限公司）的董事长兼首席执行官，负责实施买后发展战略。在此之前，Peter 曾作为首席执行官带领Guardian iT公共有限公司成立合资企业、完成管理层买出并且在伦敦证券交易所的主板成功上市。在后来的14年，在他的领导下，Guardian iT公司从一家年营业额仅为50万英镑的小公司成长为一家拥有700名员工、年营业额达1.2亿英镑并且在欧洲、南非和日本等12个国家设有分部的大型企业。在加入Guardian iT之前，Peter 曾在舍武德国际公共有限公司（Sherwood International plc），这个上市软件服务集团内担任主要董事长达10年之久，还曾在该公司的保险、金融服务和地方政府子公司担任董事总经理。
Professor Sandy Primrose PhD (音译：桑迪·普里姆罗斯)
Professor Primrose is a senior partner of Business & Technology Management, a biotechnology and healthcare consultancy practice. He was a non-executive director of the Health Protection Agency (HPA) from 2003 until March 2009. The HPA is an independent body that protects the health and well-being of the population. The Agency, which is accountable to the Secretary of State for Health, plays a critical role in protecting people from infectious diseases and in preventing harm when hazards involving chemicals, poisons or radiation occur. Previously, he was an academic at Warwick University and then held posts as Chief Operating Officer and Vice President of European Operations of Azur Environmental, Technical Director of Amersham International, and Senior Director of Drug Development at Searle Research & Development. He is a non-executive director of a number of biotechnology companies and was on the Board of the Microbiological Research Authority. He is the author of a number of well-known textbooks including 'Principles of Gene Manipulation' and 'Principles of Genome Analysis and Genomics'.
Primrose教授是商业和技术管理公司（Business & Technology Management），这家生物技术和保健咨询事务所的高级合伙人，曾在2003年到2009年3月期间担任英国卫生保护署（HPA）的非执行董事。卫生保护署是一家旨在保护人们的健康和福祉的独立机构，直接对卫生大臣负责，在防止人们感染传染性疾病和防止在发生化学品、毒物以及辐射危险时对人们造成伤害方面发挥着重要作用。此前，Primrose教授曾在华威大学从事学术工作，之后曾担任Azure环保咨询公司欧洲部的首席运营官和副总裁、阿莫仙国际（Amersham International）公司的技术主管和Searle研究与发展公司药物开发部门的高级主管。Primrose教授目前担任多家生物技术公司的非常务董事，并曾在微生物研究当局的委员会任职。此外，教授还编写了多部著名的教科书，包括《基因操纵原理》和《染色体组分析和基因组的原理》。
皇家医学会会员Jonathan Reeve FMedSci (音译：乔纳森·里夫)
Dr Reeve is a Director of Research, Bone Research, in the School of Clinical Medicine, University of Cambridge. The Clinical School comprises over 600 academic and contract research staff funded by MRC, Wellcome Trust, CRUK and other major medical charities. More than 500 NHS staff, both clinical consultants and those in professions allied to medicine, make a major contribution to the teaching and research base of the Clinical School. He began his career doing the first clinical studies on what is still the only approved pharmaceutical treatment that rebuilds bone tissue in osteoporosis (parathyroid hormone, also called PTH, and its fragments, with about 5 million patients treated). His interests since have been in doing clinical research that re-directs the focus of basic research towards clinical translation, which was one of the key outcomes of his work with PTH. In the last 15 years he has led large-scale EU-funded population-based studies on the genetic and environmental causes of osteoporotic fractures, which are ongoing. These have provided a foundation for developing sounder clinical and health economic management strategies for osteoporosis, a condition that costs over £2 billion to the UK economy each year. Current work in this area centres on unravelling the complex genetic causes of osteoporosis. His other current interests are in the mechanics of hip fracture and in mechanisms for turning on and turning off the formation of new bone at the microscopic level, malfunctions of which underlie the development of bone weakness. Here, current interest centres on molecules such as sclerostin, which the bone’s own cells make and use to regulate bone formation and which are being studied in an EU-funded project that involves several SMEs. Hip fracture is the most expensive and personally devastating fracture and occurs when the hip is exposed to major forces that it never normally experiences, typically when the victim falls sideways onto the ground. However only 50% of cases have osteoporosis and nearly all are over 70 years. With colleagues in the Department of Engineering (Cambridge) and in Melbourne Australia he has found evidence that simple ageing leads to so much thinning of the outer shell of the femur (hip bone) that it buckles on impact. Buckling can be prevented by building up the spongy bone inside the femur (eg with PTH or antibodies to sclerostin) to act as a better foundation for the weakened shell. This is an area in which several other new technologies may also offer promise.
Reeve博士是剑桥大学临床医学院骨科研究所的研究部主任。临床医学院拥有来自医学研究理事会（MRC）、威康信托基金（Wellcome Trust）、英国癌症研究院（CRUK）和其他主要医疗慈善组织的600多名在编研究人员和合同制研究人员，有500多名英国国民健康服务部门的员工，包括临床医学顾问和医药相关专业人士，他们对临床医学院的教学和研究工作做出了巨大的贡献。Reeve博士最早的临床研究是适用于骨质疏松症的药物治疗方法（甲状旁腺激素（PTH）及其碎片，已有500万病人使用该方法进行了治疗），这是在骨组织再造方面唯一经过批准的治疗方法。此后，他进行的是使基础研究更加重视临床应用的临床研究，这也是他在甲状旁腺激素研究工作领域主要的成果之一。在过去15年中，他领导了由欧盟资助的大规模人口普查，研究骨质疏松骨折的遗传学和环境原因。这项研究仍在进行中，为针对骨质疏松症开发出更好的临床和健康经济管理战略提供了基础。骨质疏松症每年给英国经济带来的代价达20多亿英镑。该领域的现在的研究集中于试图理解导致骨质疏松症的复杂的基因原因。Reeve博士目前其他的研究兴趣还有髋骨骨折的机械原理和在微观层面上开启并且关闭新骨头形成的机制、导致骨软弱症的机能失常。在这一领域，他的研究兴趣集中于分子层面，比如骨头自身的细胞产生的用以调节骨形成的硬化蛋白分子。他正在通过一项有多家中小企业参与的、欧盟资助的项目对此类分子进行研究。髋骨骨折的治疗费用非常高昂，是灾难性的骨折，通常在髋骨经受从未有过的压力时发生。比如，侧面跌倒在地时就是出现这种情况。不过，髋骨骨折的受害者中仅有50%患有骨质疏松症，几乎所有受害者的年龄都在70岁以上。Reeve博士通过与他在剑桥大学工程系和澳大利亚墨尔本的同事合作发现，年龄增长本身就会导致股骨（髋骨）外部骨架显著变薄，从而会在冲击作用下变形。如果强化股骨内部的松质骨（比如，使用甲状旁腺激素或硬化蛋白的抗体），就能为脆弱的外层提供更坚实的基础。当然，其他一些新技术也可能在该领域提供解决方案。
Laurie Rostron (音译：劳里·罗斯特伦)
Laurie Rostron has extensive experience in the healthcare industry as an investor in start-up and early stage companies and as an adviser to venture capital funds, as a non-executive director and chairman and as an industrialist. He was previously a partner in funds managed by Alta Berkeley Associates Ltd and during his 13 years with Alta Berkeley he specialised in the healthcare industry in the Nordic region. He joined Alta Berkeley Associates in 1985 following a 25 year career in the healthcare industry. This included 11 years at BOC Healthcare, where he was Managing Director of Viggo, an international intravenous therapy product business, GD Searle & Co, where he was General Manager of the Hospital Division, and Johnson & Johnson, where he was Marketing Manager of the Hospital Division. He is currently an adviser to InnovationsKapital a specialist investor in science and research-based companies in the Nordic region.
Laurie Rostron无论是作为新创公司和处于发展早期的公司的投资人，还是作为创投资本基金的顾问，无论是作为非执行董事和董事长，还是作为一名实业家，都在保健行业拥有丰富的经验。此前，他于1985年加入Alta Berkeley联营有限公司 ，在公司管理的基金里任合伙人。在Alta Berkeley 任职的13年间，Laurie专业从事北欧地区的保健行业。此前，他已经在保健行业工作长达25年，其中包括在BOC保健（BOC Healthcare）任职11年，期间担任Viggo公司（一家国际性的静脉注射治疗产品公司）的董事总经理。此外，他还曾在GD Searle & Co和强生公司任职，分别担任医院部门的总经理和市场推广部经理。他现在是InnovationsKapital公司的顾问，这是一家面向北欧地区科技和研究型公司的专业投资公司。
Sir John Treacher KCB (音译：约翰·特雷彻)
After three years at sea during WWII he qualified as a Fleet Air Arm pilot and after commanding air squadrons and ships ended his naval career as Commander-in-Chief of the Fleet. In the Ministry of Defence, he set up management of the Polaris programme and later the mating of Rolls-Royce engines with the US Navy Phantom aircraft to enable UK procurement for the Fleet Air Arm and later the RAF. After leaving the Royal Navy in 1977 to follow a business career he joined the Westland Group which was pioneering the use of new materials, fly-by-wire controls, glass cockpits and unique rotor blade design which enabled a Lynx helicopter to capture the world speed record in 1985. As marketing director he was responsible for global sales of helicopters and hovercraft and their support. He was appointed Vice Chairman in 1981 and Executive Deputy Chairman in 1983. In 1989 he became a director of Meggitt plc, a major supplier to the aerospace industry and security services, focusing on access control at airports. In 1995 he became chairman of a start up company in the fast developing communications industry, which was floated on AIM in 1997. He served as a member of the advisory board of Ozonelink Ltd, a major building security specialist company from which a subsidiary, specialising in systems for the water industry, was spun off under his chairmanship. He was elected a Fellow of the Royal Aeronautical Society in 1973, and served as a Director of the Society of British Aerospace Companies from 1982 to 1989 and as a member of the Press Council from 1978-81.
John Treacher高级巴斯勋爵士曾在第二次世界大战中在英国海军服役3年，是一位合格的的海军航空队飞行员，曾负责指挥空军中队和舰艇，担任舰队总司令，然后退役。在英国国防部任职期间，他设立了北极星计划的管理体制，此后又促成美国海军的幻影飞机使用罗尔斯·罗伊斯的引擎，使得英国可以为海军航空队和随后的皇家空军购置美国的幻影飞机。他于1977年离开皇家海军，加入Westland Group公司开始了商业生涯。Westland Group公司是一家在应用新材料、线传飞控、玻璃驾驶舱等领域开创先河的公司，采用独特的旋转机翼设计使得山猫直升机在1985年获得世界最快飞行记录。John作为市场推广总监，负责直升机、气垫船及其配套产品的全球销售。他于1981年被任命为该公司副董事长，又于1983年被任命为副执行董事长。在1989年，他成为美捷特公司公司有限公司（Meggitt plc）的一名董事，该公司是航空航天行业和安全服务领域的一家主要供应商，专业从事机场出入管制系统的研发。1995年，John 成为一家在通信行业发展迅速的新创公司（该公司于1997年成功上市）的董事长，他还曾担任Ozonelink公司顾问委员会的成员，该公司是一家专业的建筑安全公司。随后，他还曾担任由该公司分离出来的一家专业从事水行业的子公司的董事长。John 于1973年被选为英国皇家航空学会会员，并曾在1982-1989期间担任英国航空航天公司协会董事，在1978-1981年期间担任报业理事会的成员。
Professor Philip Treleaven (音译：菲利普·特里文)
Professor Philip Treleaven: Professor Treleaven is Professor of Computing at University College London and is now Director of the UK Centre for Financial Computing. Previously he was UCL Pro-Provost with responsibility for UCL's International Relations with East Asia, but also has extensive links with the Middle East. He is a European authority on electronic commerce (e.g. business on the internet, interactive TV and electronic kiosks) and on so-called 'intelligent' systems (e.g. neural networks, genetic algorithms). He published the Sunday Times sponsored e-commerce entrepreneurship book 'E-Business Start-up' and has pioneered the use of 'intelligent' computing techniques for data mining and forecasting in banking, insurance and retail. He has consulted for major American, Japanese and European high technology companies, banks and leading retailers. He was a member of the Retail & Distribution Panel of the Office of Science and Technology's Foresight Programme, and has led a DTI delegation to the US, Israel and East Asia to look at organisations and seed funding for helping high-tech start-ups. He is also an authority on the organisation of government industry programmes, such as Japan's FGCS project, the European Community's ESPRIT Programme and the UK's ALVEY/IED Programmes. He is also a co-founder of Bodymetrics, the fashion technology company.
Philip Treleaven教授是伦敦大学学院计算机运算学的教授，现在担任英国金融计算中心的董事.此前，他曾担任伦敦大学学院副校长，负责该校与东亚地区的国际关系，同时和中东地区也有广泛的联系。 Philip现在是欧洲电子商务（即通过互联网、交互电视和电子信息亭等方式进行的商务）和所谓的“智能”系统（比如，神经网络、遗传算法）方面的权威。 Philip出版了一本由《星期日泰晤士报》资助的关于电子商务行业创业精神的专著《电子商务行业的新创企业》，他还是将“智能”计算技术用于数据挖掘和对银行业、保险业和零售业进行预测的先驱者，曾为美国、日本和欧洲的多家主要高科技公司、银行和领先的零售商提供咨询服务。他还曾担任科学与技术办公室前瞻计划的零售和经销组成员，曾带领贸易与工业部代表团到美国、以色列和东亚地区考察各种组织和种子资金，旨在帮助高科技新创企业起步。他在政府与产业合作项目的组织方面是权威，非常了解日本的第五代计算机（FGCS）项目、欧洲信息技术战略研究计划（ESPRIT）和英国的ALVEY/经济发展研究院（IED）计划。此外，他还是时尚技术公司Bodymetrics的共同创始人。
David White (音译：戴维·怀特)
David White has experience of large companies and venture capital backed start-ups. He is currently a director of the UK's leading Internet physician network, Doctors.net.uk Ltd. He was previously non-executive chairman of the drug discovery company, Oxagen Limited, which is a spin-out from Oxford University/Wellcome Trust, and of Argenta Discovery (now merged with Etiologics), a drug discovery spin-out from Imperial College which was combined with an MBO from Aventis and advised by Company Guides Ltd. He was formerly Group CEO of Innovex and, following its acquisition by the US pharmaceutical and medical devices service company Quintiles Transnational, joined the board of Quintiles. He spent the first 30 years of his career in ICI, principally in the international pharmaceuticals business where his roles included being MD of Stuart Pharmaceuticals and General Manager of ICI Pharmaceuticals (UK).
David White先生在大型公司和由创投资本支持的新创建公司中工作过，目前是英国领先的外科医生网络Doctors.net.uk的董事。此前，他曾担任Oxagen 有限公司的非执行总裁，Oxagen 是一家由牛津大学/威康信托基金会派生出来的药品发现公司；他还曾担任Argenta Discovery公司的非执行总裁，这是一家由帝国理工学院派生出来的药物发现公司。Argenta Discovery公司先是与被管理层收购的Aventis公司合并，由企业指引有限公司（Company Guides Limited）提供建议，现在已与Etiologics公司合并。在此之前，David曾担任Innovex的集团首席执行官，在Innovex公司被美国的药品和医疗器械服务公司——昆泰跨国公司（Quintiles Transnational）收购后，他进入了昆泰跨国公司的董事会。David职业生涯的最初30年是在英国化学工业公司（ICI）工作，主要负责国际制药业务。在此期间，他曾担任Stuart Pharmaceuticals公司的董事总经理和英国化学工业制药（英国）公司的总经理。
Professor Florin Udrea (音译：弗罗林·乌德雷亚)
Professor Udrea is a Professor in Semiconductor Engineering and Head of the High Voltage Microelectronics and Sensors Laboratory at the University of Cambridge. He is currently leading a research group in power semiconductor devices and solid-state sensors that has won an international reputation during the last 15 years. Professor Udrea has published over 250 papers in journals and international conferences. He holds 50 patents with 30 more patent applications in power semiconductor devices and sensors. In August 2000, he co-founded, with Professor Gehan Amaratunga, Cambridge Semiconductor (CamSemi), a start-up company in the field of power integrated circuits. Its solutions are designed to help manufacturers of mains-powered electronics develop smaller, lighter and more energy-efficient products while also reducing their design timescales and system costs. It was founded in 2000 and has locations in Cambridge and Taiwan. CamSemi is one of the success stories of spin-offs from Cambridge University. The company has 70 employees worldwide and sold to date over 20M power IC units for power supplies. It has won a number of national and international awards recognising its technologies, cost-efficient products and commitment to the environment, including "University Spin-out of the Year" in the New Energy Awards 2009, Start-up of the Year from the National Microelectronics Institute in 2009, has been included four years running in Silicon 60, a list of the world's most promising technology start-ups researched and published annually by EE Times, and in 2008 was judged as Europe's third most important cleantech company by the Guardian. In August 2008, Professor Udrea, together with Professor Gardner and Professor Milne, co-founded Cambridge CMOS Sensors (CCS), a company dedicated to smart sensors for environment monitoring. The company has received seed funding from Cambridge Enterprise (Cambridge University) and was awarded an Eastern England Development Agency (EEDA) award. CCS is now developing a new generation of nano-material based gas sensors as part of a large EC consortium.
Udrea 教授是剑桥大学半导体工程系教授和高压微电子和传感器实验室的负责人，领导着一个科研小组从事功率半导体器件和固态传感器领域的研究，该研究小组在过去15年中赢得了很高的国际声誉。Udrea 教授已经在各类期刊和国际会议上发表论文250多篇，在功率半导体器件和传感器领域拥有50多项专利，另外还有30项专利正在申请。2000年8月，Udrea教授与Gehan Amaratunga共同创立了设在剑桥的英商康桥半导体公司。这是一家功率集成电路领域的新创公司，公司的解决方案旨在帮助电源驱动型电子设备制造商开发出更小、更轻、能效更高的产品，同时缩短产品的设计时间，降低系统成本。公司于2000年创立，在剑桥和台湾均设有办事处。英商康桥半导体是从剑桥大学分离出来的众多创业公司中的成功事例之一，目前在全世界拥有50名雇员，迄今为止已售出2000多万个电源集成电路单元，获得若干国家级和国际级奖项。这些奖项认可公司的技术、有成本效益的产品及对环境保护的承诺，其中包括2009年新能源奖中的“年度大学分离企业”、国家微电子学会在2009年颁发的年度创业企业大奖。此外，公司曾连续4年入选“Silicon 60”榜单（这是一份由《EE Times》每年研究并且公布的全世界最有前途的技术型创业公司名单），在2008年被英国《卫报》评为欧洲最重要的清洁技术公司第三名。2008年8月，Udrea教授与Gardner教授和Milne教授共同创立了剑桥CMOS 传感器公司（CCS），该公司致力于研发给环境监测使用的智能传感器，已经获得剑桥大学全资子公司“剑桥企业”（Cambridge Enterprise）有限公司提供的种子资金，并荣获东英格兰地区发展局（EEDA）奖项。公司加入了一个欧共体的公司集团，目前正在开发新一代基于纳米材料的气体传感器。
Please be sure to read this important legal information.
请务必认真阅读这些重要的法律信息。